In this study, GLP1-RAs did not reduce advanced therapies or corticosteroid initiation, although sensitivity analysis showed benefits of GLP1-RAs in reducing corticosteroid initiation in patients with and without obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.